tesaglitazar [orch, phsu]
promise [idcn]
Approach [spco]
Type 2 Diabetes [dsyn]
glycemia [carb]
Clinical Management [hlca]
Patients [podg]
Type 2 Diabetes [dsyn]
Comprehensive [qlco]
Approach [spco]
Address [inpr]
Abnormalities, Multiple [cgab]
Metabolic [ftcn]
Seen [qlco]
Now [tmco]
Abnormal [qlco]
Lipid Metabolism [moft]
Dyslipidaemia [dsyn]
Contribute [acty]
Markedly [qlco]
Increased [qnco]
Cardiovascular disease [dsyn]
Observed [ftcn]
diabetic [fndg]
Patients [podg]
pre-diabetic [dsyn]
Patients [podg]
signs [ftcn]
Insulin Resistance [patf]
Peroxisome Proliferator-Activated Receptors [aapp, rcpt]
Play [dora]
Regulation [gora]
energy homeostasis [biof]
Coordination [phsf]
inflammatory responses [patf]
Target [ftcn]
Address [inpr]
Glucose [bacs, carb, phsu]
Lipid [lipd]
Abnormalities [cgab]
Insulin Resistance [patf]
Thiazolidinediones [orch, phsu]
Activate [ftcn]
PPAR gamma [aapp, rcpt]
APPEAR [qlco]
glycemia [carb]
increasing insulin [dsyn]
Peripheral [spco]
Sensitivity [qnco]
Reducing [qlco]
Hepatic [blor]
Glucose [bacs, carb, phsu]
production [ocac]
Help [socb]
Beta cell [cell]
function [phsf]
effects [qlco]
Lipid [lipd]
Parameters [fndg]
Drugs [phsu]
Activate [ftcn]
PPAR alpha [aapp, rcpt]
Robust [qlco]
Improvement [cnce]
Dyslipidaemia [dsyn]
Decrease [qlco]
atherosclerotic [ftcn]
cardiovascular events [fndg]
Affect [menp]
glycemia [carb]
Compound [qlco]
Targeting [ftcn]
Alpha [inpr]
Gamma [npop]
Peroxisome Proliferator-Activated Receptors [aapp, rcpt]
simultaneously [tmco]
Combine [mnob]
Benefits [qnco]
Thiazolidinediones [orch, phsu]
Fibrates [orch, phsu]
tesaglitazar [orch, phsu]
Dual [inpr]
PPAR-alpha Agonist [phsu]
Gamma [npop]
Currently [tmco]
investigated [ftcn]
Clinical Trials, Phase III [resa]
Alternative [cnce]
treatment [ftcn]
Insulin Resistance [patf]
Type 2 Diabetes [dsyn]
Article [inpr]
Available [ftcn]
Efficacy [qlco]
Safety [hcpp]
tesaglitazar [orch, phsu]
Patients [podg]
Type 2 Diabetes [dsyn]
Diabetes [dsyn]
Insulin Resistance [patf]
Science [ocdi]
Reserve [acty]
